SCHEMBL6097867

SCHEMBL6097867

O=C(NO)C1(S(=O)(=O)N2CCC(Oc3ccc(OC(F)(F)F)cc3)CC2)CCN(Cc2ccccn2)CC1

nearest known ligand 0.68

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 6/20 0.68
MMP14 P50281 6/20 0.68
MMP3 P08254 5/20 0.68
MMP9 P14780 5/20 0.68
MMP8 P22894 5/20 0.68
MMP2 P08253 3/20 0.68
MMP13 P45452 5/20 0.53
ALDH1A1 P00352 4/20 0.50
RAB9A P51151 1/20 0.49
LMNA P02545 2/20 0.46
PKM P14618 1/20 0.46
SLC5A7 Q9GZV3 1/20 0.46
NPC1 O15118 1/20 0.45
KMT2A Q03164 2/20 0.45
MMP7 P09237 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6097006 0.91 MMP2 (0.57) MMP1MMP14MMP3MMP9MMP8
SCHEMBL6095774 0.88 MMP1 (0.54) MMP1MMP14MMP3MMP9MMP8
Hydrochloric Acid SCHEMBL6466769 0.87 MMP1 (0.53) MMP1MMP14MMP3MMP9MMP8
SCHEMBL6098789 0.86 MMP2 (0.52) MMP1MMP14MMP3MMP9MMP8
SCHEMBL6096110 0.81 MMP13 (0.55) MMP1MMP14MMP3MMP9MMP8
SCHEMBL6094181 0.81 MMP8 (0.58) MMP1MMP14MMP3MMP9MMP8
SCHEMBL6098022 0.81 MMP14 (0.66) MMP1MMP14MMP3MMP9MMP8
Hydrochloric Acid SCHEMBL6402161 0.80 MMP14 (0.65) MMP1MMP14MMP3MMP9MMP8
SCHEMBL6095979 0.80 MMP13 (0.66) MMP1MMP14MMP3MMP9MMP8
SCHEMBL6096396 0.79 ADRB2 (0.54) MMP1MMP14MMP3MMP9MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7067670-B2 Sulfamato hydroxamic acid metalloprotease inhibitor WARNER LAMBERT COMPANY (US) 2006-06-27 US disclosed
US-20050049280-A1 Sulfamato hydroxamic acid metalloprotease inhibitor PHARMACIA CORPORATION 2005-03-03 US disclosed
US-6800646-B1 Sulfamato hydroxamic acid metalloprotease inhibitor PHARMACIA CORPORATION 2004-10-05 US disclosed
US-6492367-B1 Sulfamato hydroxamic acid metalloprotease inhibitor G. D. SEARLE & COMPANY 2002-12-10 US disclosed
US-6448250-B1 INHIBITS THE ACTIVITY OF ONE OR MORE OF THE FOLLOWING MATRIX METALLOPROTEINASES: MMP-2, MMP-9, AND MMP-13, WHILE EXHIBITING SUBSTANTIALLY LESS INHIBITORY ACTIVITY AGAINST MMP-1 G. D. SEARLE & COMPANY 2002-09-10 US disclosed
EP-1157021-A1 SULFAMATO HYDROXAMIC ACID METALLOPROTEASE INHIBITOR G.D. SEARLE & CO. (US) 2001-11-28 EP disclosed
WO-2000046221-A1 SULFAMATO HYDROXAMIC ACID METALLOPROTEASE INHIBITOR G.D. SEARLE & CO. (US) 2000-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049280-A1 Sulfamato hydroxamic acid metalloprotease inhibitor MMP14, MMP12, MMP17 MMP1 4/4885MMP14 1/4885MMP3 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.